New drug rozanolixizumab tested for rare Muscle-Weakening disease in china
NCT ID NCT07246564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug rozanolixizumab in 40 Chinese adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive the drug as a shot under the skin. The main goal is to see if it improves their ability to do daily activities after about 6 weeks. This is an early, small study without a comparison group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mg0033 20040
RECRUITINGBeijing, China
-
Mg0033 20172
RECRUITINGShanghai, China
-
Mg0033 20180
RECRUITINGWuhan, China
-
Mg0033 20184
RECRUITINGShenzhen, China
-
Mg0033 20185
RECRUITINGJinan, China
-
Mg0033 20204
RECRUITINGSuzhou, China
-
Mg0033 20261
RECRUITINGChangchun, China
-
Mg0033 20269
RECRUITINGGuangzhou, China
-
Mg0033 20295
RECRUITINGChangsha, China
-
Mg0033 20347
RECRUITINGJinan, China
-
Mg0033 20348
RECRUITINGFuzhou, China
-
Mg0033 20349
RECRUITINGXuzhou SHI, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rozanolixizumab
What this could lead to
If successful, this could provide a new treatment option for Chinese patients with generalized myasthenia gravis, improving daily function.
What could go wrong
This is a small, single-arm, open-label study with no placebo group, so results may be less reliable. It only covers one treatment cycle, and long-term safety and efficacy are not assessed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.